Phase II trial with temozolomide in children with recurrent high-grade glioma.

Antonio Ruggiero, Cesare Colosimo, Ilaria Lazzareschi, Palma Maurizi, Vita Ridola, Massimo Caldarelli, Concezio Di Rocco, Riccardo Riccardi, G. Cefalo, M. L. Garré, M. Massimino, E. Madon, M. E. Abate, A. Clerico, A. Sandri

Risultato della ricerca: Contributo in rivistaArticolo in rivista

41 Citazioni (Scopus)

Abstract

PURPOSE: The objective of the study was to evaluate the efficacy and toxicity of Temozolomide (TMZ) administered for 5 consecutive days in three daily dosing in children with recurrent or refractory high-grade glioma. PATIENTS AND METHODS: Twenty-four patients with a median age of 10.5 years were enrolled onto this open-label, multicenter, phase II study. The patients were previously treated with surgical resection (17 of 24), radiotherapy (19 of 24) and chemotherapy (18 of 24). Therapy was administered orally three times a day for 5 consecutive days at the dose of 200 mg/m(2)/dx5 for chemotherapy naive patients. In patients heavily pretreated with chemotherapy the starting dose was of 150 mg/m(2)/dx5. RESULTS: A total of 95 cycles were administered. The median progression free-survival (PFS) was 3 months for the entire group while disease stabilization was obtained in 7 patients (29.1%), all with supratentorial tumors. No CR or PR was observed. TMZ treatment showed a limited toxicity. Thrombocytopenia was the most common hematological adverse effect. Our data suggest a marginal activity of TMZ in children with recurrent high-grade glioma.
Lingua originaleEnglish
pagine (da-a)89-94
Numero di pagine6
RivistaJournal of Neuro-Oncology
Volume77
Stato di pubblicazionePubblicato - 2005

Keywords

  • children
  • high-grade glioma
  • temozolomide

Fingerprint Entra nei temi di ricerca di 'Phase II trial with temozolomide in children with recurrent high-grade glioma.'. Insieme formano una fingerprint unica.

Cita questo